黄连组方对2型糖尿病患者血清瘦素、脂联素的影响

The effect of Coptidis Rhizoma-Composed Prescription on serum leptin and adiponectin in type 2 diabetic patients

目的观察黄连组方对超重或肥胖的2型糖尿病(T2DM)患者血清瘦素(Lep)、脂联素(APN)的影响。方法采用随机、平行对照、前瞻性研究方法,将250例患者随机分为两组,分别口服黄连组方(治疗组)或二甲双胍片(对照组);服药12周后,比较HbA_1c、FPG、2hPG、BMI、WC、血清Lep及APN,分析黄连组方对了2DM患者的影响。结果治疗组服药后HbA_1c、FPG、2hPG、BMI、WC均较服药前显著下降,差异有统计学意义(P<0.05)。治疗组与对照组比较,差异无统计学意义(P>0.05)。治疗组治疗后血清Lep较治疗前下降(P<0.05),APN与治疗前相比无明显变化。结论黄连组方可改善T2DM患者高血糖,且具有一定的减肥作用,其疗效与普通二甲双胍片相似。

Objective To observe the effect of Coptidis Rhizoma-Composed Prescription（CRCP） on serum leptin（Lep） and adiponectin（APN） in overweight or obese type 2 diabetic patients. Methods Multicenter, paralleled, prospective clinical trail recruited 250 cases who were randomly divided into 2 groups （n= 125 ,each）. Treatment group were treated with CRCP and control, with metformin. The levels of HbA1c, FPG, 2hPG, BMI,WC, Lep and APN were compared between the two groups after 12 weeks. Results The levels of HbA1c,FPG,2hPG, BMI and WC were significantly reduced after treatment versus baseline in both CRCP group and metformin group （all P 〈 0. 05）, but were not significantly different between CRCP and metformin treatment groups in both baseline and post-treatment （all P 〈 0. 05）. In CRCP group Lep declined distinctly compared to the baseline （P 〈 0.05） while APN was not. Conclusions Coptidis Rhizoma Composing Prescription can improve high blood sugar status of type 2 diabetic patients and has some role in losing the weight. The effects are identical to metformin.